Global Phase 2 Randomized Trial of BNT327 (Pumitamig; PD-L1 × VEGF-A bsAb) + Chemotherapy for 1 L ES-SCLC: Dose Optimization Analysis - Heymach, J V (2025)
Oral Session OA13.02